



OPEN ACCESS

## EXTENDED REPORT

# Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population

Suzanne M M Verstappen,<sup>1</sup> Mark Lunt,<sup>1</sup> Robert N Luben,<sup>2</sup> Jackie Chipping,<sup>3</sup> Tarnya Marshall,<sup>3</sup> Kay-Tee Khaw,<sup>2</sup> Nick Wareham,<sup>2</sup> William G Dixon,<sup>1</sup> Ian N Bruce,<sup>1</sup> Deborah P M Symmons<sup>1,4</sup>

**Handling editor** Tore K Kvien

► Additional data are published online only. To view this file please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2012-201698>).

<sup>1</sup>Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK

<sup>2</sup>Department of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Cambridge, UK

<sup>3</sup>Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, UK

<sup>4</sup>NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, UK

## Correspondence to

Dr Suzanne M M Verstappen, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK; Suzanne.Verstappen@manchester.ac.uk

Received 17 March 2012

Accepted 11 September 2012

Published Online First

13 October 2012

## ABSTRACT

**Objectives** To identify demographic and clinical predictors of obstructive lung disease (OLD) and restrictive lung disease (RLD) in patients with established inflammatory polyarthritis (IP) and to compare the prevalence of respiratory symptoms in patients with IP and the general population.

**Method** A total of 421 patients with IP underwent a spirometry test 15 years after inclusion in the Norfolk Arthritis Register (NOAR). Logistic regression analyses were performed to assess the predictive ability of demographic and clinical characteristics obtained at inclusion in NOAR and to assess their association with OLD or RLD at 15 years (age- and gender-adjusted). In addition, the prevalence of OLD and RLD was compared with a matched population (1:4) of people participating in the European Prospective Investigation of Cancer-Norfolk, a representative sample of the general population in Norfolk, UK.

**Results** In this IP population, current smoking was the strongest predictor for OLD and functional disability for RLD. In the comparison study, 11.6% had OLD in the IP population and 4.9% in the general population (adjOR 2.01, 95% CI 1.26 to 3.22). The prevalence of RLD was not statistically different between the IP population and the general population (14.6% vs 17.5%; adjOR 0.76, 95% CI 0.53 to 1.10).

**Conclusions** OLD, but not RLD, is more prevalent in the IP population than in the general population. Functional disability is especially associated with RLD whereas smoking is associated with OLD. The latter finding, and the known association between smoking and a poor disease prognosis, underlines the importance of smoking cessation in patients with IP.

## INTRODUCTION

Respiratory manifestations in rheumatoid arthritis (RA) are common and include upper and lower airway disorders, pleural and interstitial disorders including RA-associated interstitial lung disease (RA-ILD) and are associated with increased mortality.<sup>1–7</sup> Common lung disorders can be divided into obstructive lung disease (OLD), including chronic obstructive bronchitis and emphysema, and restrictive lung disease (RLD), including RA-ILD. Especially for RLD, prevalence rates vary widely

ranging from 1% to 50%, depending on the diagnostic tests used (eg, pulmonary function tests, high-resolution CT (HRCT)) and the population studied.<sup>1</sup> As there is an increased prevalence of smoking in patients with RA, it is perhaps not surprising that there should also be an increased prevalence of chronic obstructive pulmonary disease, lung cancer and respiratory infections compared with the general population. However, even after adjustment for smoking, increased rates of respiratory symptoms have been found in patients with RA compared with the general population.<sup>8,9</sup>

Several demographic and disease severity measures such as male gender, age, smoking, body mass index (BMI), erythrocyte sedimentation rate, rheumatoid factor (RF), anti-citrullinated protein antibody (ACPA) and human leucocyte antigen (HLA)-B40 have been identified as predictors of lung disease in patients with RA,<sup>2,10–13</sup> although results differ between studies and sample sizes are relatively small. Moreover, most studies were restricted to investigating the prevalence and predictors of either OLD or RLD but not of both. Another disadvantage of previous publications is the cross-sectional study design. For some associations observed, such as between decreased functional disability and OLD or RLD, it is not possible to establish the direction of the association. Therefore, it is also important to determine the association between potential predictors measured prior to the pulmonary function test and subsequent lung function disorders.

The objectives of this study were (1) to identify potential demographic and clinical predictors measured 15 years prior to and potential variables associated with OLD and RLD at time of the spirometry test in patients with inflammatory polyarthritis (IP), and (2) to compare the prevalence of abnormal lung function in patients with IP and the general population.

## METHODS

### Clinical assessments

Consecutive patients aged over 16 years with early IP from the Norfolk Arthritis Register (NOAR) recruited between 1990 and 1994 were included in this study. Details of NOAR have been published previously.<sup>14</sup> Briefly, patients with swelling in two



Open Access  
Scan to access more  
free content

or more joints that lasted  $\geq 4$  weeks were referred to NOAR. At baseline, patients were seen by a research nurse. Clinical assessments included the evaluation of the number of swollen and tender joints (out of a total of 51). Blood was collected and stored in  $-80^{\circ}\text{C}$  freezers to measure RF (positive  $>40$  UI), ACPA ( $\geq 5$  U/ml; Axis-Shield DIASTAT Kit, Axis-Shield, Dundee, UK) and C-reactive protein (CRP, mg/l). HLA genotyping was carried out as described previously and subtyping at the *HLA-DRB1* locus was performed to identify the presence of the shared epitope.<sup>15</sup> The 28-joint Disease Activity Score, based on three components including C-reactive protein (DAS28(3) CRP)<sup>16</sup> was calculated for each patient. In addition, patients completed the British version of the Health Assessment Questionnaire (HAQ).<sup>17</sup> At each follow-up visit, smoking status was recorded and categorised into never smoked/past smoker/current smoker at baseline and 15-year follow-up. Clinical follow-up assessments were carried out annually for 3 years and then at 5, 7, 10, 12 and 15 years. RA was defined according to the 1987 American College of Rheumatology (ACR) criteria<sup>18</sup> and applied cumulatively over these years. At each assessment the use of disease-modifying antirheumatic drugs (DMARDs) and other medication, including medication for respiratory diseases (see online supplemental file), were also recorded. In NOAR, all patients remain under long-term follow-up except for (1) patients who do not cumulatively satisfy the ACR criteria for RA at 5 years and have been given a consultant diagnosis other than RA, undifferentiated IP, psoriatic arthritis or post-viral arthritis to explain their symptoms; (2) patients whose disease has gone into spontaneous long-term remission (no inflamed joints at the 3rd or 5th anniversary and not on DMARDs or steroids).

### Respiratory function in patients with IP

A respiratory function test was performed at the 15-year assessment by a research nurse using a portable spirometer (Micro Medical GP MS07). A standardised protocol was used. Exclusion criteria were patients with angina, undiagnosed chest pains, cardiac problems, recent abdominal or eye surgery or frailty. Forced expiratory volume in 1 s ( $\text{FEV}_1$ ), percentage predicted  $\text{FEV}_1$  ( $\text{FEV}_1\text{pred}$ ), forced vital capacity (FVC) and percentage predicted FVC (FVCpred) were recorded. OLD was defined according to British Thoracic Society criteria (ie,  $\text{FEV}_1/\text{FVC} < 0.70$  and  $\text{FEV}_1\text{pred} < 80\%$ ).<sup>19</sup> RLD was defined as  $\text{FVCpred} < 70\%$  and  $\text{FEV}_1/\text{FVC}$  between 0.80 and 1.00. Normal lung function was defined as  $\text{FVCpred} \geq 70\%$  and  $\text{FEV}_1\text{pred} \geq 80\%$ . Patients also completed the Medical Research Council (MRC) respiratory symptom questionnaire.<sup>20 21</sup> The MRC dyspnoea scale consists of five statements about perceived breathlessness (see figure 1).

Patients with MRC grades 3, 4 or 5 were defined as having moderate to severe breathlessness and were compared with patients with MRC grades 1 or 2.

<b>Grade I:</b> I only get breathless with strenuous exercise
<b>Grade II:</b> I get short of breath when hurrying on the level or up a slight hill exercise
<b>Grade III:</b> I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level or up a slight hill exercise.
<b>Grade IV:</b> I stop for breath after walking 100 yards or after a few minutes on the level
<b>Grade V:</b> I am too breathless to leave the house

**Figure 1** Description grades of MRC respiratory symptom questionnaire.

### Respiratory function in the general population

Respiratory data collected as part of the European Prospective Investigation of Cancer (EPIC-Norfolk) in Norfolk, UK were used as reference data for the general population.<sup>22 23</sup> Participants in EPIC-Norfolk are men and women aged 39–79 years at inclusion into the cohort and resident in Norfolk, UK—that is, the same residential area as that of the patients in NOAR. Participants in EPIC-Norfolk were recruited between 1993 and 1997 and follow-up data have been collected at regular intervals. For the present study, data obtained during the second assessment (1998–2000) were used. Participants were asked to complete a questionnaire including questions about any medical conditions, medication use and smoking history (never, past or current). At a clinic visit, height and weight were measured and respiratory function was assessed by spirometry (Micro Medical, Rochester, UK).  $\text{FEV}_1$  and FVC were measured twice and the higher measure was recorded. Participants in EPIC-Norfolk who were also included in NOAR, were using DMARDs, had a diagnosis of RA, had incomplete respiratory data or missing data on height were excluded from the general population cohort in this study.

### Comparison of respiratory function between patients with IP and the general population

Since the age range between patients with IP and the general population sample was slightly different and age is strongly associated with lung function, we included only those people aged between 42 and 81 years at the time the respiratory test was performed. Patients with IP were matched 1–4 with people from the general population by age, gender and season in which the spirometry test was performed. By season and gender, controls were matched using a greedy algorithm to select age matches by selecting the closest match first, within a 5-year age range, then the closest remaining match and so on (STATA, gmatch).  $\text{FEV}_1\text{pred}$  and  $\text{FVCpred}$  were not recorded in EPIC and therefore we estimated the expected  $\text{FEV}_1$  and FVC for both cohorts to calculate the percentage of predicted value (observed/estimated expected  $\times 100\%$ ). The estimated expected value was calculated based on the equation from the Health Survey for England.<sup>24</sup> The estimated  $\text{FEV}_1\text{pred}$  and  $\text{FVCpred}$  values were strongly correlated with the actual recorded  $\text{FEV}_1\text{pred}$  and  $\text{FVCpred}$  values within the NOAR cohort ( $\text{FEV}_1\text{pred}$ :  $r=0.97$ ,  $p<0.001$ ;  $\text{FVCpred}$ :  $r=0.96$ ,  $p<0.001$ ).

NOAR and EPIC-Norfolk were approved by the local Norwich Research Ethics Committee and all patients and participants gave written informed consent.

### Statistical analysis

In the IP population the predictive ability of baseline demographic and disease-related characteristics and the association between demographic and disease related factors measured at

15 years with OLD or RLD at the 15-year follow-up were assessed using logistic regression models. OR (95% CI) were adjusted for age and gender (adjOR). For the comparison study between patients with IP and the general population, a multinomial regression analysis was performed to test the difference in smoking rates between patients with IP and the general population. A random linear or logistic effect model, where appropriate, retaining the matched groups, was applied to test the difference in FEV<sub>1</sub> and FVC between patients with IP and the general population and to test the likelihood for OLD and RLD adjusting for smoking status (adj $\beta$  or adjOR). All analyses were repeated in the group of patients fulfilling the 1987 ACR criteria for RA.

All analyses were carried out using STATA Release 11 (StataCorp, College Station, Texas, USA).

## RESULTS

A total of 1098 eligible patients were recruited by NOAR between 1990 and 1994; 304 died before the expected 15-year follow-up assessment date, in 12% of which the underlying cause of death was respiratory disease (ICD-10 code J\*, see online supplement). In addition, 271 patients were lost to follow-up or were not followed after the 5-year assessment as indicated by the protocol. A total of 523 patients were seen for their 15-year assessment. Of these, 102 patients fulfilled the exclusion criteria or did not want to perform the spirometry test, leaving 421 patients with complete respiratory data included in this study.

At 15 years the mean (SD) age of these 421 patients was 62 (13) years and mean disease duration since symptom onset was 16.0 (1.1) years; 68% were female (table 1) and 79.3% cumulatively fulfilled the 1987 ACR criteria for RA. Disease activity was moderate with a median (IQR) DAS28 score of 3.0 (2.2–3.9) and a median HAQ score of 0.88 (0.25–1.63). Thirty-nine percent of the patients were using non-biological DMARDs and about 6% used a biological agent.

### Abnormal lung function test

Mean (SD) FEV<sub>1</sub> and FVC were slightly higher for men than for women (2.65 (0.77) l vs 2.10 (0.60) l and 3.39 (0.94) l vs 2.62 (0.73) l, respectively). 6.1% of female patients and 17.1% of male patients satisfied the criteria for OLD and 6.9% of female patients and 24.7% of male patients satisfied the criteria for RLD. Forty-seven of 421 patients (11%) were not categorised as having OLD, RLD or normal lung function. In the total IP population, 12.4% used medication for respiratory symptoms. Of the 419 patients who completed the MRC respiratory questionnaire, 14.1% (14.7% of women and 12.8% of men) reported being breathless ( $\geq$ grade 3).

### Associations with OLD and RLD

Table 2 shows the baseline predictors of abnormal lung function test at 15 years. Age and male gender were predictors of both OLD and RLD in patients with IP. Current smoking at baseline (adjOR 15.25, 95% CI 3.14 to 73.99) and a trend towards previous smoking (adjOR 4.59, 95% CI 0.99 to 21.33) were strong predictors of OLD. DAS28 measured at baseline (adjOR 1.41, 95% CI 1.00 to 1.99) was also a predictor of OLD. No other clinical variables were associated with OLD, whereas RLD was predicted by a high baseline tender joint count (adjOR 1.07, 95% CI 1.02 to 1.12), worse DAS28 score (adjOR 1.44, 95% CI 1.09 to 1.91) and higher HAQ score (adjOR 2.28, 95% CI 1.36 to 3.83). In addition, patients who fulfilled the 1987 criteria for RA (adjOR 2.56, 95% CI 1.24 to 5.29) and

**Table 1** Demographic, clinical characteristics and spirometry values at 15 years

Variable	N	
<b>Demographic characteristics</b>		
Age, years	421	62 (13)
Gender, female	421	288 (68.4%)
Disease duration, years	415	16.0 (1.1)
BMI	421	27 (24–31)
Smoking status	421	
Never		141 (33.5%)
Past		217 (51.5%)
Current		63 (15.0%)
<b>Clinical characteristics</b>		
Swollen joint count, 28-joint count	421	0 (0–3)
Tender joint count, 28-joint count	421	2 (0–6)
DAS28 <sub>CRP(3)</sub>	325	3.0 (2.2–3.9)
HAQ	420	0.88 (0.25–1.63)
CRP, mg/l	325	9.0 (3.6–17.0)
RF*, positive	376	98 (26.1%)
ACPA*, positive	323	74 (22.9%)
Shared epitope:	392	
0 allele		159 (40.6%)
1 allele		170 (43.4%)
2 alleles		63 (16.1%)
RA, 1987 criteria	421	334 (79.3%)
Nodules	421	44 (10.5%)
<b>Medication use</b>		
nbDMARD	421	166 (39.4%)
Biologics	421	26 (6.2%)
Oral steroids	421	47 (11.2%)
<b>Abnormal lung function test</b>		
FEV <sub>1</sub>	421	2.28 (0.70)
Men		2.65 (0.77)
Women		2.10 (0.60)
FVC	421	2.86 (0.88)
Men		3.39 (0.94)
Women		2.62 (0.73)
Obstructive lung disease†	333	30 (9.0%)
Men		15 (17.1%)
Women		15 (6.1%)
Restrictive lung disease†	344	41 (11.9%)
Men		24 (24.7%)
Women		17 (6.9%)
Medication for respiratory symptoms	421	52 (12.4%)
Breathlessness	419	59 (14.1%)

N=number of patients with available data. Values are mean (SD), median (IQR) for continuous variables or n (%) for categorical variables.

\*Measured at baseline.

†Compared with patients with normal spirometry lung function test (see Methods section for description of obstructive, restrictive and normal spirometry lung function test).

ACPA, anti-citrullinated protein antibody; BMI, body mass index; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; FEV<sub>1</sub>, forced expiratory volume in 1 s; FVC, forced vital capacity; HAQ, Health Assessment Questionnaire; nbDMARD, non-biological disease-modifying antirheumatic drug; RA, rheumatoid arthritis; RF, rheumatoid factor.

patients with nodules (adjOR 4.79, 95% CI 1.46 to 15.71) at baseline were more likely to have RLD 15 years after inclusion in the NOAR cohort. To further test the association between clinical and demographic characteristics measured early in the disease with the development of lung disease, the analyses were repeated excluding patients (n=12) who used drugs for respiratory symptoms at baseline since we did not perform a

**Table 2** Baseline predictors of obstructive and restrictive lung disease

	N=303	Normal	Obstructive lung disease			Restrictive lung disease		
			N	Obstructive N=30	OR (95% CI)	N	Restrictive N=41	OR (95% CI)
<b>Demographic characteristics</b>								
Age, years	303	44 (13)	30	53 (9)	<b>1.06 (1.02 to 1.09)</b>	41	51 (13)	<b>1.04 (1.01 to 1.07)</b>
Gender, female	303	230 (76%)	30	15 (50%)	<b>0.32 (0.15 to 0.68)</b>	41	17 (41%)	<b>0.22 (0.11 to 0.44)</b>
Smoking status	303		30			41		
Never		112 (37%)		2 (7%)	1		13 (32%)	1
Past		123 (41%)		14 (47%)	4.59 (0.99 to 21.33)		16 (39%)	0.64 (0.28 to 1.50)
Current		68 (22%)		14 (47%)	<b>15.25 (3.14 to 73.99)</b>		12 (29%)	1.45 (0.59 to 3.56)
<b>Clinical characteristics</b>								
Swollen joint count, 28 joints	303	4 (1–9)	30	5 (2–11)	1.01 (0.96 to 1.08)	41	6 (3–14)	1.05 (1.00 to 1.11)
Tender joint count, 28 joints	303	5 (2–10)	30	4 (1–15)	1.04 (0.99 to 1.10)	41	7 (3–13)	<b>1.07 (1.02 to 1.12)</b>
DAS28 <sub>CRP(3)</sub>	251	3.70 (2.75–4.60)	22	4.12 (3.53–4.88)	<b>1.41 (1.00 to 1.99)</b>	33	4.10 (3.35–5.68)	<b>1.44 (1.09 to 1.91)</b>
HAQ	297	0.625 (0.25–1.13)	30	0.563 (0.38–1.0)	1.01 (0.55 to 1.87)	41	0.875 (0.38–1.63)	<b>2.28 (1.36 to 3.83)</b>
CRP, mg/l	251	3 (0–9)	22	4 (8.5–13)	1.00 (0.99 to 1.02)	33	9 (2–17)	1.00 (0.99 to 1.02)
RF, positive	274	64 (23%)	24	9 (38%)	2.27 (0.90 to 5.75)	36	12 (33%)	1.63 (0.74 to 3.58)
ACPA, positive	246	54 (22%)	17	3 (18%)	0.70 (0.19 to 2.60)	24	10 (42%)	2.25 (0.90 to 5.63)
Shared epitope	283		29			36		
0 allele		116 (41%)		9 (31%)	1		15 (42%)	1
1 allele		122 (43%)		14 (48%)	1.44 (0.58 to 3.57)		15 (42%)	0.86 (0.39 to 1.93)
2 alleles		45 (16%)		6 (21%)	1.79 (0.57 to 5.64)		6 (17%)	0.96 (0.33 to 2.80)
RA, 1987 criteria	303	121 (40%)	30	12 (40%)	0.94 (0.42 to 2.14)	41	24 (59%)	<b>2.56 (1.24 to 5.29)</b>
Nodules	303	13 (4%)	30	3 (10%)	2.60 (0.64 to 10.59)	41	5 (12%)	<b>4.79 (1.46 to 15.71)</b>

N=number of patients with available data. Values are mean (SD), median (IQR) for continuous variables or n (%) for categorical variables.

See Methods section for description of obstructive, restrictive and normal spirometry lung function test.

Bold type indicates statistical significance (p<0.05).

ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor; RLD, restrictive lung disease.

spirometry test at baseline and thus could not define patients as having OLD or RLD at baseline. DAS28 was no longer a predictor for OLD (p=0.062), probably because of lack of power, whereas all other results remained the same.

Cross-sectional associations between demographic and clinical variables with OLD and RLD at 15 years are shown in table 3. Age and male gender at the 15-year follow-up were associated with OLD and RLD. Current smoking at 15 years (adjOR 15.91, 95% CI 3.00 to 84.3) and also previous smoking (adjOR 5.90, 95% CI 1.32 to 26.4) were associated with OLD at 15 years. This could probably be explained by the 51 patients who were smoking at baseline and stopped smoking during follow-up. Among all the patients who stopped smoking prior to the 15-year follow-up visit and with available data on time of smoking cessation (n=148), the risk of having OLD reduced with longer cessation time (OR 0.98, 95% CI 0.94 to 1.02) although this was not significant.

Patients with a high DAS28 were more likely to have OLD (adjOR 1.49, 95% CI 1.05 to 2.10) but not RLD (adjOR 1.22, 95% CI 0.83 to 1.80). In contrast, patients with decreased functional ability were more likely to have RLD (adjOR 2.90, 95% CI 1.78 to 4.71) and a trend for OLD (adjOR 1.60, 95% CI 0.96 to 2.66). High BMI (adjOR 1.08, 95% CI 1.00 to 1.16) was associated with RLD and, although not significant, there was a trend towards an association between CRP (adjOR 1.01, 95% CI 1.00 to 1.03), nodules (adjOR 2.22, 95% CI 0.88 to 5.57) and RLD. Use of steroids at the time of the 15-year assessment was associated with RLD, but use of methotrexate did not differ between patients with lung function abnormalities and those without. Restricting the analyses to patients who cumulatively fulfilled the 1987 ACR criteria for RA resulted in similar findings (see online supplementary file tables S1 and S2).

### Comparison of abnormal lung function test between patients with IP and the general population

This part of the study included 373 patients with IP and 1492 people from the general population in Norfolk, UK (table 4). The mean (SD) age in both cohorts was 62 (11) years and 68% were women. Patients with IP were more often current smokers (relative risk ratio (RRR) 2.76, 95% CI 1.89 to 4.02) or ex-smokers (RRR 1.97, 95% CI 1.54 to 2.52) than people from the general population. Although a small difference, FEV<sub>1</sub> was significantly lower for patients with IP than in the general population (adjβ -0.08, 95% CI -0.13 to -0.02) but FVC was similar between the two populations (adjβ 0.06, 95% CI -0.01 to 0.13) with adjustment for smoking. However, when adjusting for smoking and BMI, patients with IP were less likely to have RLD than the general population (table 4). Thirty-two of 277 patients (11.6%) had OLD in the IP population compared with 55/1124 (4.9%) in the general population (adjOR 2.01, 95% CI 1.26 to 3.22); for women and men these figures were, respectively, 18/197 (9.1%) vs 25/789 (3.2%) (adjOR 2.47, 95% CI 1.29 to 4.71) and 14/80 (17.5%) vs 30/335 (9.0%) (adjOR 1.76, 95% CI 0.87 to 3.58). RLD was observed in 14.6% (42/287) of the IP population and in 17.5% (227/1296) of the general population (adjOR 0.76, 95% CI 0.53 to 1.10). Eleven percent (22/201) women with IP and 13.4% (118/882) women in the general population had RLD (adjOR 0.77, 95% CI 0.47 to 1.28). In men these percentages were 23.3% (20/86) and 26.3% (109/414), respectively (adjOR 0.82, 95% CI 0.47 to 1.43). Overall, patients with IP used medication for respiratory symptoms more often than people from the general population (12.1% vs 2.8%) (OR 4.84, 95% CI 2.91 to 8.06).

**Table 3** Associations of obstructive and restrictive lung disease: cross-sectional analysis at 15 years

	N	Normal	Obstructive lung disease			Restrictive lung disease		
			N	Obstructive N=30	OR (95% CI)	N	Restrictive N=41	OR (95% CI)
Demographic characteristics								
Age, years	303	60 (13)	30	69 (10)	<b>1.06 (1.02 to 1.09)</b>	41	67 (13)	<b>1.04 (1.01 to 1.07)</b>
Gender, female	303	230 (76%)	30	15 (50%)	<b>0.32 (0.15 to 0.68)</b>	41	17 (41%)	<b>0.22 (0.11 to 0.44)</b>
BMI	303	27.5 (4.9)	30	28.0 (5.4)	1.02 (0.94 to 1.10)	41	29.2 (5.1)	<b>1.08 (1.00 to 1.16)</b>
Smoking status	303		30			41		
Never		112 (37%)		2 (7%)	1		13 (32%)	1
Past		154 (51%)		20 (67%)	<b>5.90 (1.32 to 26.4)</b>		19 (46%)	0.68 (0.30 to 1.51)
Current		37 (12%)		8 (27%)	<b>15.91 (3.00 to 84.3)</b>		9 (22%)	2.01 (0.74 to 5.50)
Clinical characteristics								
Swollen joint count, 28 joints	303	0 (0–3)	30	1 (0–3)	1.05 (0.94 to 1.17)	41	0 (0 to 3)	1.01 (0.91 to 1.13)
Tender joint count, 28 joints	303	2 (0–6)	30	2 (0–10)	1.05 (1.00 to 1.11)	41	1 (0 to 7)	1.04 (0.99 to 1.09)
DAS28 <sub>CRP(3)</sub>	237	2.97 (2.18–3.80)	28	3.46 (2.32–4.43)	<b>1.49 (1.05 to 2.10)</b>	24	3.05 (2.43 to 3.67)	1.22 (0.83 to 1.80)
HAQ	302	0.75 (0.13–1.5)	30	0.94 (0.38–1.88)	1.60 (0.96 to 2.66)	41	1.50 (0.88 to 2.0)	<b>2.90 (1.78 to 4.71)</b>
CRP, mg/l	237	8.5 (3.1–14.5)	28	11.7 (6.3–20.5)	1.01 (0.99 to 1.03)	24	17.7 (6.5 to 24.7)	1.01 (1.00 to 1.03)
RA, 1987 criteria	303	236 (78%)	30	24 (80%)	1.00 (0.37 to 2.66)	41	37 (90%)	2.57 (0.85 to 7.78)
Nodules	303	31 (10.2%)	30	1 (3.3%)	0.32 (0.04 to 2.51)	41	8 (20%)	2.22 (0.88 to 5.57)
Current Methotrexate use	303	84 (28%)	30	7 (23%)	0.67 (0.27 to 1.68)	41	6 (15%)	0.42 (0.16 to 1.06)
Current oral steroids use	303	23 (8%)	30	6 (20%)	2.23 (0.77 to 6.42)	41	10 (24%)	<b>3.22 (1.30 to 7.98)</b>
Respiratory symptoms								
Medication for respiratory symptoms	303	32 (11%)	30	8 (27%)	<b>3.68 (1.42 to 9.55)</b>	41	6 (15%)	1.66 (0.61 to 4.52)
Breathlessness	301	33 (11%)	30	8 (27%)	<b>2.80 (1.09 to 7.20)</b>	41	9 (22%)	2.28 (0.93 to 5.58)

N=number of patients with available data. Values are mean (SD), median (IQR) for continuous variables or n (%) for categorical variables.

See Methods section for description of obstructive, restrictive and normal spirometry lung function test.

Bold type indicates statistical significance ( $p < 0.05$ ).

BMI, body mass index; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; RLD, restrictive lung disease.

## DISCUSSION

In this study of patients with established IP, 9.0% had OLD and 11.9% had RLD. The percentage with OLD was higher than in the general population matched for age and gender. We found a strong association between smoking and OLD, an association not observed with RLD. A number of measures of disease severity assessed early in the disease were mainly predictive of RLD after 15 years. However, DAS28 was the only clinical variable

associated with OLD in both the longitudinal and the cross-sectional analysis. Nodules, another extra-articular manifestation of RA, were also associated with RLD.

In previous studies inconsistent results have been found between measures of disease activity, demographic factors, smoking and RLD and OLD.<sup>2 10–13</sup> The findings of our study are supported by prior studies that have identified clinical and other demographic factors in association with either RLD or

**Table 4** Comparison of spirometry data for patients with IP and the general population

Variable	N/n	Mean (SD) or n (%) General population (N=1492)	Mean (SD) or n (%) IP patients (N=373)	Difference: $\beta$ (95% CI) or OR (95% CI) Adjusted for smoking	Difference: $\beta$ (95% CI) or OR (95% CI) Adjusted for smoking and BMI
Demographic characteristics					
Age, years	1492/373	62 (11)	62 (11)		
Gender, female	1492/373	1012 (68%)	253 (68%)		
Smoking status					
Never		767 (51.4%)	125 (33.5%)		
Past		607 (40.7%)	195 (52.3%)		
Current		118 (7.9%)	53 (14.2%)		
BMI, kg/m <sup>2</sup>	1490/373	26.6 (4.1)	27.9 (5.0)		
Abnormal lung function test					
Medication for respiratory symptoms	1492/373	41 (2.8%)	45 (12.1%)		
FEV <sub>1</sub>	1492/373	2.36 (0.71)	2.28 (0.69)	−0.08 (−0.13 to −0.02)	−0.06 (−0.11 to −0.01)
FVC	1492/373	2.82 (0.87)	2.88 (0.86)	0.06 (−0.01 to 0.13)	0.08 (0.01 to 0.15)
Obstructive lung disease	1124/277	55 (4.9%)	32 (11.6%)	2.01 (1.26 to 3.22)	2.05 (1.27 to 3.29)
Restrictive lung disease	1296/287	227 (17.5%)	42 (14.6%)	0.76 (0.53 to 1.10)	0.71 (0.49 to 1.03)

N=general population/n=patients with IP with available data.

BMI, body mass index; FEV<sub>1</sub>, forced expiratory volume in 1 s; FVC, forced vital capacity; IP, inflammatory polyarthritis.

OLD with respect to HAQ, BMI, male gender and age. However, in contrast to other studies,<sup>10</sup> we did not find a significant association between ACPA and RF and lung function abnormalities, but a trend between RF at baseline and OLD and a trend between ACPA at baseline and RLD at 15 years was observed. We did not find an association between smoking and RLD, whereas a strong association between smoking and RA-ILD was found in a previous study defining RA-ILD by means of carbon monoxide transfer factor,  $FVC < 80\%$  pred and perfusion abnormality.<sup>12</sup> Smoking, especially current smoking, was strongly associated with OLD, an observation previously observed in both the general population<sup>25–26</sup> and RA population.<sup>10</sup>

Only a few other studies have investigated the association between demographic and clinical factors and both OLD and RLD in the same IP/RA cohort. In one study, including 159 patients with RA without cardiovascular disease and with a mean disease duration of 10 years, breathlessness, BMI and prednisone use were predictors of RLD, and chronic cough, prior diagnosis of lung disease, gender, exercise, BMI, current smoking, RF positivity and prednisone use were predictors of OLD in a final multivariate regression model.<sup>10</sup> In our study we found an association between breathlessness and OLD, but not with RLD in univariate regression analysis. The MRC respiratory symptom questionnaire used in the present study was developed to detect respiratory symptoms, a surrogate marker of chronic obstructive pulmonary disease (COPD), and thus our results seem valid. The association between oral steroids and abnormal lung function tests found in our study and in the previous study may be a reflection of worse disease activity or because they are prescribed because of their lung disease.

Pulmonary toxicity of methotrexate has been reported in a number of studies<sup>27–29</sup> but not in other investigations.<sup>30</sup> Since methotrexate is the DMARD of first choice in most countries, we also investigated the association between methotrexate use and lung function test abnormalities in this study. Cross-sectionally, we did not find worse lung function in those patients who used methotrexate in the total population, but a protective effect was found in those with RA. We also analysed the effect of methotrexate use since symptom onset on lung function test abnormalities (data not shown), and again no association was found. This may be due to channelling bias, by which methotrexate treatment is avoided or discontinued in those with respiratory problems. Alternatively, the lack of association could reflect the fact that methotrexate pulmonary toxicity leads to either a severe pneumonitis (in which case the patient may be lost to follow-up) or a self-limiting pneumonitis from which the patient fully recovers when methotrexate is discontinued.

A number of problems arise when comparing results of lung function disorders in RA populations based on spirometry tests, especially RLD between studies. In contrast to OLD for which generally accepted criteria are available (ie,  $FEV_{1\text{pred}} \leq 80\%$  and  $FEV_1/FVC < 0.70$ ), no internationally accepted pulmonary function test criteria exist for RLD. Furthermore, the comparison group varies between studies. In our study, patients with RLD and OLD were compared with patients with normal lung function defined as  $FVC_{\text{pred}} \geq 70\%$  and  $FEV_{1\text{pred}} \geq 80\%$  at 15 years. It is, however, possible that some patients with OLD at 15 years had RLD at baseline and vice versa.

The second objective of this study was to compare the prevalence of an abnormal lung function test in patients with IP and the general population in Norfolk, UK. OLD occurred more frequently in patients with IP than in the general population after adjusting for smoking, as previously observed.<sup>9</sup> In another study the prevalence of pulmonary function abnormalities was

also higher in non-smoking patients with RA compared with the general population.<sup>8</sup> Although RA-ILD is the most common form of lung involvement in RA and we did find an association between worse disease and RLD in this study, RLD was not more evident in the IP population than in the general population. Since RLD, once clinically apparent, rather than OLD is especially associated with increased mortality in RA,<sup>1–2</sup> it is possible that those patients with the most severe RLD did not survive to the 15-year follow-up (see online supplemental file for a description of underlying causes of death) or were no longer participating in the study.

This study has some limitations. RLD was not confirmed by any other test such as HRCT.<sup>31–32</sup> The findings regarding the comparison of an abnormal lung function test between the IP population and the general population should particularly be interpreted with caution. The protocol used to assess  $FEV_1$  and FVC differed between the two cohorts. In order to define patients with OLD and RLD we had to estimate the expected  $FEV_1$  and FVC based on equations derived from the English population. Although the estimated and actual reading of both  $FEV_{1\text{pred}}$  and  $FVC_{\text{pred}}$  were strongly correlated, it is known that the prevalence of COPD may vary between areas in the UK.<sup>33</sup> The difference in the obtained  $FEV_1$  value was small but statistically significant and the difference in the percentage of patients with OLD between the two populations was relatively large. A slight change in the value may already define whether or not a person has OLD or RLD. This was noticeable when a few patients with IP who were identified as having OLD based on the actual measurement no longer had OLD when the  $FEV_{1\text{pred}}$  was calculated again for the comparison study, although a strong correlation existed between the obtained  $FEV_{1\text{pred}}$  and the calculated  $FEV_{1\text{pred}}$ . Clinically, it is therefore important to perform other diagnostic tests as well. Another limitation is that those patients with IP with, for example, cardiovascular diseases or who were frail were excluded from this study whereas no exclusion criteria were applied in the EPIC cohort. This may have led to an underestimate of the true difference in abnormal lung function tests between the IP population and the general population because of the increased likelihood of abnormal lung function tests in people with these comorbidities.

In conclusion, OLD (but not RLD) is more prevalent in an established IP population than in the general population. Functional disability is especially associated with RLD whereas smoking is associated with OLD. The latter finding and the known association between smoking and a poor disease prognosis—and the better prognosis in those who stopped—strengthens the importance of smoking cessation in patients with inflammatory arthritis.

**Acknowledgements** We would like to acknowledge the contribution of the local general practitioners and rheumatologists in Norwich in referring patients to the register, the NOAR metrologists in the collection of the clinical data and the database management team in Manchester.

**Contributors** All authors contributed to the design of the study, interpretation of the results and approval of final version of the manuscript.

**Funding** NOAR is funded by Arthritis Research UK (grant reference 17552).

**Competing interests** None.

**Ethics approval** Ethics approval was obtained from the Norwich local research ethics committee, UK.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

## REFERENCES

- Nannini C**, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. *Curr Opin Rheumatol* 2008;**20**:340–6.
- Tureson C**, O'Fallon WM, Crowson CS, *et al*. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis* 2003;**62**:722–7.
- Bartels CM**, Bell CL, Shinki K, *et al*. Changing trends in serious extra-articular manifestations of rheumatoid arthritis among United State veterans over 20 years. *Rheumatology (Oxford)* 2010;**49**:1670–5.
- Metafratzi ZM**, Georgiadis AN, Ioannidou CV, *et al*. Pulmonary involvement in patients with early rheumatoid arthritis. *Scand J Rheumatol* 2007;**36**:338–44.
- Koduri G**, Norton S, Young A, *et al*. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. *Rheumatology (Oxford)* 2010;**49**:1483–9.
- Naz SM**, Symmons DP. Mortality in established rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2007;**21**:871–83.
- Amital A**, Shitrit D, Adir Y. The lung in rheumatoid arthritis. *Presse Med* 2011;**40**:e31–48.
- Fuld JP**, Johnson MK, Cotton MM, *et al*. A longitudinal study of lung function in nonsmoking patients with rheumatoid arthritis. *Chest* 2003;**124**:1224–31.
- Geddes DM**, Webley M, Emerson PA. Airways obstruction in rheumatoid arthritis. *Ann Rheum Dis* 1979;**38**:222–5.
- Pappas DA**, Giles JT, Connors G, *et al*. Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study. *Arthritis Res Ther* 2010;**12**:R104.
- Gabbay E**, Tarala R, Will R, *et al*. Interstitial lung disease in recent onset rheumatoid arthritis. *Am J Respir Crit Care Med* 1997;**156**:528–35.
- Saag KG**, Kolluri S, Koehnke RK, *et al*. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. *Arthritis Rheum* 1996;**39**:1711–19.
- Charles PJ**, Sweatman MC, Markwick JR, *et al*. HLA-B40: a marker for susceptibility to lung disease in rheumatoid arthritis. *Dis Markers* 1991;**9**:97–101.
- Symmons DP**, Barrett EM, Bankhead CR, *et al*. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. *Br J Rheumatol* 1994;**33**:735–9.
- Thomson W**, Harrison B, Ollier B, *et al*. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. *Arthritis Rheum* 1999;**42**:757–62.
- Prevo ML**, van't Hof MA, Kuper HH, *et al*. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;**38**:44–8.
- Kirwan JR**, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. *Br J Rheumatol* 1986;**25**:206–9.
- Arnett FC**, Edworthy SM, Bloch DA, *et al*. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;**31**:315–24.
- National Clinical Guideline Centre**. Management of adults with chronic obstructive pulmonary disease in primary and secondary care: update guideline (draft). NICE, 2009. <http://www.nice.org.uk/nicemedia/pdf/COPDraftConsultationGuideline.pdf>
- Bestall JC**, Paul EA, Garrod R, *et al*. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax* 1999;**54**:581–6.
- Medical Research Council**. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. *Lancet* 1965;**1**:775–9.
- Day N**, Oakes S, Luben R, *et al*. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. *Br J Cancer* 1999;**80** (Suppl 1):95–103.
- McFadden E**, Luben R, Wareham N, *et al*. How far can we explain the social class differential in respiratory function? A cross-sectional population study of 21,991 men and women from EPIC-Norfolk. *Eur J Epidemiol* 2009;**24**:193–201.
- Falaschetti E**, Laiho J, Primatesta P, *et al*. Prediction equations for normal and low lung function from the Health Survey for England. *Eur Respir J* 2004;**23**:456–63.
- Purdy S**, Griffin T, Salisbury C, *et al*. Emergency respiratory admissions: influence of practice, population and hospital factors. *J Health Serv Res Policy* 2011;**16**:133–40.
- Shavit O**, Swern A, Dong Q, *et al*. Impact of smoking on asthma symptoms, healthcare resource use, and quality of life outcomes in adults with persistent asthma. *Qual Life Res* 2007;**16**:1555–65.
- Kremer JM**, Alarcon GS, Weinblatt ME, *et al*. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum* 1997;**40**:1829–37.
- Salliot C**, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis* 2009;**68**:1100–4.
- Verstappen SM**, Bakker MF, Heurkens AH, *et al*. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. *Ann Rheum Dis* 2010;**69**:1044–8.
- Dawson JK**, Graham DR, Desmond J, *et al*. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. *Rheumatology (Oxford)* 2002;**41**:262–7.
- Youssef AA**, Machaly SA, El-Dosoky ME, *et al*. Respiratory symptoms in rheumatoid arthritis: relation to pulmonary abnormalities detected by high-resolution CT and pulmonary functional testing. *Rheumatol Int* 2012;**32**:1985–95.
- Biederer J**, Schnabel A, Muhle C, *et al*. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. *Eur Radiol* 2004;**14**:272–80.
- Nacul L**, Soljak M, Samarasinghe E, *et al*. COPD in England: a comparison of expected, model-based prevalence and observed prevalence from general practice data. *J Public Health (Oxf)* 2011;**33**:108–16.

## **Supplementary file**

Supplementary file of manuscript entitled "Demographic and disease related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population".

Suzanne MM Verstappen, Mark Lunt, Robert N Luben, Jackie Chipping, Tarnya Marshall, K-T Khaw, N Wareham, WG Dixon, IN Bruce and DPM Symmons

### *Overview medication for respiratory symptoms:*

Ventolin, aerolin, ventodisks, terbutataline, bricanyl, eformoterol, foradil, ipratropium, atrovent, combivent, duovent, salmeterol, serevent, oxis, formoterol, beclomethasone, dipropionate, becotide, becloforte, aerobec, beclazone, becodisk, qvar, budesonide, pulmicort, fluticasone propionate, flixotide, seretide.

### *Underlying causes of death*

Overview of underlying causes of death (ICD10 code; n=number of patients) in patients who died because of respiratory diseases before the 15 year follow-up visit: pneumonia (J18.0, n=11); lobar pneumonia, unspecified (J18.1, n=1); pneumonia, unspecified (J18.9, n=4); emphysema (J43, n=1); emphysema, unspecified (J44.9, n=11); asthma (J45, n=1); pneumonitis due to food and vomit (J69.0, n=1); adult respiratory distress syndrome (J80, n=1); pulmonary oedema (J81, n=1); other interstitial pulmonary diseases with fibrosis (J84.1); and respiratory disorder, unspecified (J98.9, n=1).

**Table S1.** Baseline predictors of obstructive and restrictive lung disease in patients cumulatively fulfilling the 1987 ACR criteria for RA..

	N	Obstructive lung disease			Restrictive lung disease			
		Normal N=236	N	Obstructive N=24	OR (95%CI)	N	Restrictive N=37	OR (95%CI)
<i>Demographic characteristics</i>								
Age, years	236	45 (13)	24	52 (10)	<b>1.05 (1.01 to 1.08)</b>	37	51 (13)	<b>1.04 (1.01 to 1.06)</b>
Gender, female	236	183 (78%)	24	12 (50%)	<b>0.29 (0.12 to 0.68)</b>	37	16 (43%)	<b>0.22 (0.11 to 0.45)</b>
Smoking status	236		24			37		
Never		89 (37%)		1 (4%)	1		13 (35%)	1
Past		95 (40%)		12 (50%)	7.93 (0.98 to 63.97)		14 (38%)	0.57 (0.23 to 1.39)
Current		52 (22%)		11 (46%)	<b>26.24 (3.08 to 223.71)</b>		10 (27%)	1.38 (0.53 to 3.60)
<i>Clinical characteristics</i>								
Swollen joint count, 28 joints	236	6 [2 – 11]	24	7 [2.5 – 11.5]	1.02 (0.96 to 1.09)	37	7 [3 – 14]	1.04 (0.98 to 1.10)
Tender joint count, 28 joints	236	5 [2 – 11]	24	4 [1 – 19]	1.04 (0.98 to 1.10)	37	9 [4 – 13]	<b>1.06 (1.01 to 1.11)</b>
DAS28 <sub>CRP(3)</sub>	194	4.00 [3.13 – 4.85]	17	4.54 [3.70 – 5.79]	1.32 (0.89 to 1.97)	29	4.40 [3.59 – 5.90]	<b>1.45 (1.06 to 1.99)</b>
HAQ	230	0.625 [0.25 – 1.25]	24	0.75 [0.38 – 1.2]	0.99 (0.51 to 1.92)	37	1.25 [0.38 – 1.63]	<b>2.15 (1.24 to 3.70)</b>
CRP, mg/L	194	4.5 [0.2 – 12]	17	8 [5 – 11]	0.99 (0.97 to 1.02)	29	10 [2 – 18]	1.00 (0.99 to 1.02)
RF, positive	214	59 (28%)	19	8 (42%)	2.27 (0.82 to 6.26)	32	12 (38%)	1.63 (0.72 to 3.69)
ACPA, positive	189	52 (28%)	13	3 (23%)	0.75 (0.19 to 2.93)	21	10 (48%)	2.29 (0.87 to 6.05)
Shared epitope:	221		23			32		
0 allele		89 (40%)		7 (30%)	1		13 (41%)	1
1 allele		95 (43%)		10 (43%)	1.33 (0.47 to 3.77)		14 (44%)	0.89 (0.38 to 2.11)
2 alleles		37 (17%)		6 (26%)	2.01 (0.60 to 6.75)		5 (16%)	0.79 (0.24 to 2.55)
Nodules	236	13 (6%)	24	3 (13%)	2.68 (0.65 to 11.00)	37	5 (14%)	<b>4.17 (1.27 to 13.72)</b>

N = number of patients with available data. Values are mean (SD), median [IQR] for continuous variables or numbers (%) for categorical variables. DAS28 = 28 joint Disease Activity Score; HAQ = Health assessment Questionnaire; CRP = C-reactive protein; ACPA = anti-citrullinated protein antibody ; RF = Rheumatoid Factor; RA = Rheumatoid Arthritis. See patients and methods for description of obstructive, restrictive and normal spirometry lung function test. OR (95%CI) = odds ratio and 95% confidence interval. Bold numbers = statistically significant (p<0.05).

**Table S2.** Associations of obstructive and restrictive lung disease: Cross-sectional analysis at 15 year in patients cumulatively fulfilling the 1987 ACR criteria for RA.

	Obstructive lung disease			Restrictive lung disease				
	N	Normal N=236	N	Obstructive N=24	OR (95%CI)	N	Restrictive N=37	OR (95%CI)
<i>Demographic characteristics</i>								
Age, years	236	61 (13)	24	68 (10)	<b>1.04 (1.00 to 1.08)</b>	37	67 (13)	<b>1.04 (1.01 to 1.07)</b>
Gender, female	236	183 (76%)	24	12 (50%)	<b>0.29 (0.12 to 0.68)</b>	37	16 (43%)	<b>0.22 (0.11 to 0.45)</b>
BMI	236	27.5 (5.0)	24	27.7 (4.7)	1.02 (0.93 to 1.12)	37	29 (5.3)	1.07 (1.00 to 1.16)
Smoking status	236		24			37		
Never		89 (38%)		1 (4%)	1		13 (35%)	1
Past		120 (51%)		17 (71%)	<b>10.26 (1.31 to 80.15)</b>		16 (43%)	0.57 (0.24 to 1.34)
Current		27 (11%)		6 (25%)	<b>26.48 (2.85 to 246.19)</b>		8 (23%)	2.21 (0.75 to 6.45)
<i>Clinical characteristics</i>								
Swollen joint count, 28 joints	236	1 [0 – 3]	24	1 [0 – 4]	1.05 (0.94 to 1.17)	37	0 [0 to 3]	0.99 (0.88 to 1.10)
Tender joint count, 28 joints	236	2 [0 – 6]	24	2 [0 – 11]	1.04 (0.98 to 1.10)	37	1 [0 to 7]	1.02 (0.97 to 1.08)
DAS28 <sub>CRP(3)</sub>	195	3.04 [2.22 – 4.07]	22	3.46 [2.10 – 4.43]	1.35 (0.92 to 1.98)	24	3.15 [2.44 to 3.73]	1.16 (0.76 to 1.77)
HAQ	235	0.88 [0.25 – 1.63]	24	1.06 [0.56 – 1.81]	1.56 (0.89 to 2.72)	37	1.625 [1.0 to 2.0]	<b>2.66 (1.59 to 4.42)</b>
CRP, mg/L	195	8.8 [3.5 – 16.4]	22	9.3 [5.9 – 23.1]	1.01 (0.99 to 1.03)	24	18.3 [6.5 to 25.2]	1.01 (1.00 to 1.03)
Nodules	236	30 (12.7%)	24	1 (4.2%)	0.32 (0.04 to 2.49)	37	8 (22%)	1.96 (0.77 to 4.95)
Current Methotrexate use	236	80 (34%)	24	5 (21%)	0.45 (0.16 to 1.29)	37	5 (14%)	<b>0.28 (0.10 to 0.78)</b>
Current oral steroids use	236	23 (10%)	24	5 (21%)	1.94 (0.63 to 6.03)	37	10 (27%)	<b>2.86 (1.15 to 7.12)</b>
<i>Respiratory symptoms</i>								
Medication for respiratory symptoms	236	26 (11%)	24	8 (33%)	<b>4.98 (1.81 to 7.77)</b>	37	5 (14%)	1.55 (0.52 to 4.61)
Breathlessness	234	31 (13%)	24	7 (29%)	<b>2.81 (1.02 to 7.77)</b>	37	7 (19%)	1.71 (0.64 to 4.53)

N = number of patients with available data. Values are mean (SD), median [IQR] for continuous variables or numbers (%) for categorical variables. DAS28 = 28 joint Disease Activity Score;

HAQ = Health assessment Questionnaire; CRP = C-reactive protein; ACPA = anti-citrullinated protein antibody ; RF = Rheumatoid Factor; RA = Rheumatoid Arthritis. See patients and methods for description of obstructive, restrictive and normal spirometry lung function test. OR (95%CI) = odds ratio and 95% confidence interval. Bold numbers = statistically significant (p<0.05).

**Table S3.** Comparison spirometry data in patients cumulatively fulfilling the 1987 ACR criteria for RA and the general population.

Variable	N/n	Mean (SD) or n (%) General population N=1176	Mean (SD) or n (%) IP patients N=294	Difference: $\beta$ (95%CI) or OR (95%CI) Adjusted for smoking	Difference: $\beta$ (95%CI) or OR (95%CI) Adjusted for smoking and BMI
<i>Demographic characteristics</i>					
Age, years	1176/294	63 (11)	63 (11)		
Gender, female	1176/294	804 (68%)	201 (68%)		
Smoking status					
Never		609 (51.8%)	102 (34.7%)		
Past		477 (40.6%)	155 (52.7%)		
Current		90 (7.6%)	37 (12.6%)		
BMI, kg/m <sup>2</sup>	1174/294	26.6 (4.0)	28.0 (5.1)		
<i>Abnormal lung function test</i>					
Medication for respiratory symptoms	1492/373	32 (2.7%)	35 (11.9%)		
FEV1*	1176/294	2.33 (0.70)	2.25 (0.67)	<b>-0.08 (-0.14 to -0.01)</b>	-0.06 (-0.12 to -0.003)
FVC*	1176/294	2.78 (0.85)	2.84 (0.83)	0.05 (-0.03 to 0.13)	0.07 (-0.04 to 0.15)
Obstructive lung disease*	871/217	45 (5.2%)	25 (11.5%)	<b>1.89 (1.12 to 3.20)</b>	<b>1.91 (1.12 to 3.26)</b>
Restrictive lung disease*	1010/229	184 (18.2%)	37 (16.2%)	0.84 (0.56 to 1.26)	0.78 (0.52 to 1.18)

N = general population / n = IP patients with available data. \* adjusted for smoking status.